Flu Shots Rarely Work for People Over Age 65
For the 2014-2015 “flu season,” the reported effectiveness of the annual flu shot was only 14% in those over age 50. It has been long recognized that elderly people do not respond well to vaccination as a whole and that their immune responses to annual influenza vaccinations are especially weak. The elderly are at higher risk for serious complications from infections…
Jacobson v. Massachusetts: State Police Powers Affirmed
In its 1905 precedent setting split decision in the case of Jacobson v. Massachusetts, the U.S. Supreme Court, by a 7-2 vote, ruled that state legislatures could use police powers to force a minority of dissenting citizens to use smallpox vaccine for what medical doctors and government officials judge to be the greater good of the majority. Those voting with the majority were…
The “Greater Good”: A Raw Deal for Muggles
Whenever you hear someone advocating “for the Greater Good,” run away as fast as you can. Either that, or take the person on aggressively. Be aware that that concept has been used by people throughout history to commit some of the worst, most heinous crimes against humanity. Adolph Hitler immediately comes to mind. His goal was to purify the human race by…
Ben Hammond Suffered Brain Inflammation/ADEM After Tdap Vaccine
Getting Flu Shots Regularly May Increase Susceptibility to the Flu
Data collected from Canada and Hong Kong during 2009-2010 showed that people who received the seasonal flu vaccine in 2008 had twice the risk of getting the H1N1 “swine flu” compared to those who hadn’t received a flu shot. ABC News reported at that time that such shots may actually set you up for less “broad” protection than if you get, and recover from, a natural…
U.S. Vaccine Market Forecast at $17.4 Billion by 2018
The value of the market for vaccines in the United States will reach $17.4 billion in 2018, according to a study published by Transparency Market Research of Albany, NY. If accurate, the projection would represent a compound annual growth rate (CAGR) of 5.3% during 2012-2018. TMR estimated the US vaccine market at $12.8 billion in 2012. TMR attributes its optimistic forecast to…